Navigation Links
Catch and release
Date:11/12/2012

BOSTON, MAA research team at Brigham and Women's Hospital has developed a novel device that may one day have broad therapeutic and diagnostic uses in the detection and capture of rare cell types, such as cancer cells, fetal cells, viruses and bacteria. The device is inspired by the long, elegant appendages of sea creatures, such as jellyfish and sea cucumbers.

The study will be published online on November 12, 2012 in Proceedings of the National Academy of Sciences.

The device, a microchip, is inspired by a jellyfish's long, sticky tentacles that are used to capture miniscule food flowing in the water. The researchers designed a chip that uses a three-dimensional DNA network made up of long DNA strands with repetitive sequences thatlike the jellyfish tentaclescan detect, bind and capture certain molecules.

The researchers, led by Jeffrey Karp, PhD, BWH Division of Biomedical Engineering, Department of Medicine at Brigham and Women's Hospital, senior study author, and Rohit Karnik, PhD, Massachusetts Institute of Technology, co-author, created the chip using a microfluidic surface and methods that allowed them to rapidly replicate long DNA strands with multiple targeting sites that can bind to cancer cells, but also custom tailor critical characteristics, such as DNA length and sequence which would allow them to target various cell types.

In this study, Karp and his team tested the chip using a DNA sequence that had a specific affinity to a cell-surface protein found abundantly in human cancer cells.

The researchers engineered the device to efficiently capture a higher quantity of cancer cells from whole blood patient samples at much higher flow rates compared to other methods that use shorter DNA strands or antibodies.

"The chip we have developed is highly sensitive. From just a tiny amount of blood, the chip can detect and capture the small population of cancer cells responsible for cancer relapse," said Weian Zhao, PhD, a postdoctoral fellow from the Karp lab who is now faculty at the University of California, Irvine, and first study author.

In addition to using the device for blood-based cancers, it may find application to isolate cells that break away from solid tumors and travel through the bloodstream.

"What most people don't realize is that it is the metastasis that kills, not the primary tumor," said Karp. "Our device has the potential to catch these cells in the act with its 'tentacles' before they may seed a new tumor in a distant organ."

Moreover, unlike other methods, the device was able to maintain a high purity of the captured cells that could easily be released and cultured in the laboratory.

"One of the greatest challenges in the treatment of cancer patients is to know which drug to prescribe," said Karp. "By isolating circulating tumor cells before and after the first round of chemotherapy is given, we can determine the biology behind why certain cells are resistant to chemotherapy. We can also use the isolated cells to screen drugs for personalized treatments that could boost effectiveness and hopefully prevent cancer relapse."


'/>"/>
Contact: Marjorie Montemayor-Quellenberg
mmontemayor-quellenberg@partners.org
617-534-2208
Brigham and Women's Hospital
Source:Eurekalert  

Related medicine news :

1. Heat, rainfall affect pathogenic mosquito abundance in catch basins
2. CSHL Press releases new book on the biology of drug addiction
3. Institute for Population Health Improvement releases buyers guide for health information exchange
4. Premier global health journal, The Lancet, releases series on universal health coverage
5. Evidence that new biomimetic controlled-release capsules may help in gum disease
6. PMIC Announces Release of New CDT 2013 Dental Procedure Coding System
7. Muscular Development Store Releases the Optimum Performance Workout for High Intensity Training
8. MTSS-mba Membership Benefits Administration Software for Private and Taft-Hartley Employee Benefit Funds Releases New Pension Modules
9. Candeo Partners with Catholic Church Organization to Release New Sexual Addiction Recovery Program
10. GMC Denali Road Bike Review Released Today By GMCDenaliRoadBike.net
11. Waterpik Water Flosser Reviews Released Today By WaterpikReviews.net
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Catch and release
(Date:7/21/2017)... ... July 21, 2017 , ... MedMatchPlus+ has ... chances of acceptance to a residency in a United States hospital. Being accepted ... the U.S. , According to data released by the ECFMG®, every year, 50 ...
(Date:7/21/2017)... ... July 21, 2017 , ... Sharon ... the signature product of her research center at Bio-Logic Aqua Research® Water Life ... and the greatest number of sufferers of blindness. “We think that Nature’s Tears® ...
(Date:7/21/2017)... ... July 21, 2017 , ... In the ... from the Multicenter Orthopaedics Outcome Network (MOON) demonstrated that patients could perform sports-related ... though activity levels decline over time. The study, presented today at the ...
(Date:7/21/2017)... ONTARIO, CANADA (PRWEB) , ... July 21, 2017 ... ... give insight into why concussion rates are on the rise, say researchers presenting ... Meeting today in Toronto, Ontario, Canada. , “The combination of evaluating the patterns ...
(Date:7/20/2017)... ... 2017 , ... ChenMed , a leading provider of value-based care for ... as Richmond Chief Medical Officer. Dr. McCarter, formerly Associate Professor of Family ... of Ambulatory Services for the UVA Health System, brings 30 years of highly relevant ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... RESEARCH TRIANGLE PARK, N.C. , July ... UTHR ) announced today that it will report ... opens on Thursday, July 27, 2017. ... on Thursday, July 27, 2017, at 9:00 a.m. Eastern ... international callers dialing 1-970-315-0533.  A rebroadcast of the teleconference ...
(Date:7/20/2017)... -- Prime Therapeutics LLC (Prime) released this statement from its Chief ... for Clinical and Economic Review,s (ICER) public meeting ... of abuse-deterrent formulations (ADF) of opioids. Prime was the sole ... "The ICER data ... use of abuse-deterrent formulations (ADF) in opioids in terms of ...
(Date:7/15/2017)... Enterin Inc., a Philadelphia -based ... today announced the completion of a $12.7 million Series A ... as well as the participation of existing investors. ... the support of New Ventures III and our current investors, ... the potential of our platform technology to transform the course ...
Breaking Medicine Technology: